Please assess the completion status of the following clinical trial:

Trial Title: Early Endoscopy for Acute Upper Gastrointestinal Bleeding in Acute Coronary Syndrome Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with recent (\< 2 weeks) ACS and acute upper GI bleeding accompanied with a decrease in hemoglobin (Hb) level greater than 2 g/dl~Exclusion Criteria (if any one of the following criteria is present):~* Malignancy or other advanced disease with a life expectancy of \< 6 months~* Pregnant or lactating women~* History of allergy or severe side effects to PPIs, contrast, and iodine~* Bleeding tendency, and platelet count \< 80k/uL, prothrombin time INR \>2.0~* Decompensated liver cirrhosis (Child-Pugh classification B\~C) and esophagogastric varices history~* Stage 3\~5 CKD (estimated Ccr \< 60 ml/min/1.73m2) using Cockcroft-Gault formula, exclusive of end-stage renal disease under renal replacement therapy~* Stigmata of hemorrhage confirmed as lower GI tract bleeders~* Without informed consents

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- early endoscopy (Type: EXPERIMENTAL): endoscopic hemostasis
- without early endoscopy (Type: NO_INTERVENTION): Patients assigned to non-endoscopic treatment group receive high dose infusional PPI therapy. If UGI bleeding subsided after medical treatment alone, diagnostic EGD will be done under stable hemodynamic and 2 weeks after ACS to confirm UGI SRH. If the SRH is not located at UGI tract, the patients will be excluded. Troponin I or T and complete ECG will be checked every 8 hours within 24 hours of interventions. APACHE II score at intervention will be calculated for each patient.

Based on this trial design, predict the completion outcome and termination type (if applicable).